Diagnostic Medical Systems S.A.
Diagnostic Medical Systems S.A. (DGM.PA) Stock Competitors & Peer Comparison
See (DGM.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGM.PA | €1.20 | +0.00% | 0 | -4.43 | -€0.27 | N/A |
| PHIA.AS | €23.60 | +0.85% | 22.2B | 25.10 | €0.93 | +3.64% |
| IBAB.BR | €13.10 | +2.83% | 380.4M | 30.19 | €0.43 | +1.85% |
| ALERS.PA | €21.25 | -2.75% | 207.4M | 93.64 | €0.22 | N/A |
| ALMDT.PA | €4.64 | +5.82% | 170.7M | -3.91 | -€1.16 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| EAPI.PA | €1.31 | +2.99% | 124.4M | -1.00 | -€1.31 | N/A |
| GBT.PA | €9.30 | -6.72% | 121.4M | -1.08 | -€8.91 | N/A |
| AFME.PA | €2.81 | +0.00% | 110.4M | -7.81 | -€0.36 | N/A |
| SEQUA.BR | €0.52 | +11.63% | 37.4M | -0.39 | -€1.23 | N/A |
Stock Comparison
DGM.PA vs PHIA.AS Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, PHIA.AS has a market cap of 22.2B. Regarding current trading prices, DGM.PA is priced at €1.20, while PHIA.AS trades at €23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas PHIA.AS's P/E ratio is 25.10. In terms of profitability, DGM.PA's ROE is -0.23%, compared to PHIA.AS's ROE of +0.08%. Regarding short-term risk, DGM.PA is more volatile compared to PHIA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check PHIA.AS's competition here
DGM.PA vs IBAB.BR Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, IBAB.BR has a market cap of 380.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while IBAB.BR trades at €13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas IBAB.BR's P/E ratio is 30.19. In terms of profitability, DGM.PA's ROE is -0.23%, compared to IBAB.BR's ROE of +0.10%. Regarding short-term risk, DGM.PA is more volatile compared to IBAB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check IBAB.BR's competition here
DGM.PA vs ALERS.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALERS.PA has a market cap of 207.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALERS.PA trades at €21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALERS.PA's P/E ratio is 93.64. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALERS.PA's ROE of +0.01%. Regarding short-term risk, DGM.PA is more volatile compared to ALERS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALERS.PA's competition here
DGM.PA vs ALMDT.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALMDT.PA has a market cap of 170.7M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALMDT.PA trades at €4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALMDT.PA's P/E ratio is -3.91. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALMDT.PA's ROE of +0.59%. Regarding short-term risk, DGM.PA is more volatile compared to ALMDT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALMDT.PA's competition here
DGM.PA vs ALCOR.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, DGM.PA is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALCOR.PA's competition here
DGM.PA vs EAPI.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, EAPI.PA has a market cap of 124.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while EAPI.PA trades at €1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas EAPI.PA's P/E ratio is -1.00. In terms of profitability, DGM.PA's ROE is -0.23%, compared to EAPI.PA's ROE of -0.24%. Regarding short-term risk, DGM.PA is more volatile compared to EAPI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check EAPI.PA's competition here
DGM.PA vs GBT.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, GBT.PA has a market cap of 121.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while GBT.PA trades at €9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas GBT.PA's P/E ratio is -1.08. In terms of profitability, DGM.PA's ROE is -0.23%, compared to GBT.PA's ROE of -0.34%. Regarding short-term risk, DGM.PA is less volatile compared to GBT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check GBT.PA's competition here
DGM.PA vs AFME.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, AFME.PA has a market cap of 110.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while AFME.PA trades at €2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas AFME.PA's P/E ratio is -7.81. In terms of profitability, DGM.PA's ROE is -0.23%, compared to AFME.PA's ROE of -0.57%. Regarding short-term risk, DGM.PA is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check AFME.PA's competition here
DGM.PA vs SEQUA.BR Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, SEQUA.BR has a market cap of 37.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while SEQUA.BR trades at €0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas SEQUA.BR's P/E ratio is -0.39. In terms of profitability, DGM.PA's ROE is -0.23%, compared to SEQUA.BR's ROE of +1.24%. Regarding short-term risk, DGM.PA is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check SEQUA.BR's competition here
DGM.PA vs MKEA.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, DGM.PA is priced at €1.20, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, DGM.PA's ROE is -0.23%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, DGM.PA is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check MKEA.PA's competition here
DGM.PA vs ALIMP.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALIMP.PA has a market cap of 29.3M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALIMP.PA trades at €0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALIMP.PA's P/E ratio is -5.10. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALIMP.PA's ROE of +13.76%. Regarding short-term risk, DGM.PA is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check ALIMP.PA's competition here
DGM.PA vs ALNOV.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALNOV.PA has a market cap of 27.2M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALNOV.PA trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALNOV.PA's P/E ratio is -0.82. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALNOV.PA's ROE of -0.15%. Regarding short-term risk, DGM.PA is more volatile compared to ALNOV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALNOV.PA's competition here
DGM.PA vs ALDMS.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALDMS.PA has a market cap of 26.3M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALDMS.PA trades at €1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALDMS.PA's P/E ratio is -9.69. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALDMS.PA's ROE of -0.13%. Regarding short-term risk, DGM.PA is more volatile compared to ALDMS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALDMS.PA's competition here
DGM.PA vs ALIKO.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALIKO.PA has a market cap of 23.1M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALIKO.PA trades at €1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALIKO.PA's P/E ratio is -6.35. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, DGM.PA is more volatile compared to ALIKO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALIKO.PA's competition here
DGM.PA vs ALTHE.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALTHE.PA has a market cap of 20.2M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALTHE.PA trades at €0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALTHE.PA's P/E ratio is -3.90. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALTHE.PA's ROE of +4.68%. Regarding short-term risk, DGM.PA is less volatile compared to ALTHE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check ALTHE.PA's competition here
DGM.PA vs ALTER.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, DGM.PA is more volatile compared to ALTER.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALTER.PA's competition here
DGM.PA vs ALEMG.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALEMG.PA has a market cap of 13.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALEMG.PA trades at €4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALEMG.PA's P/E ratio is 12.39. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALEMG.PA's ROE of -0.33%. Regarding short-term risk, DGM.PA is more volatile compared to ALEMG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALEMG.PA's competition here
DGM.PA vs ALBLU.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALBLU.PA has a market cap of 9M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALBLU.PA trades at €0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALBLU.PA's P/E ratio is -8.17. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALBLU.PA's ROE of -0.71%. Regarding short-term risk, DGM.PA is more volatile compared to ALBLU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALBLU.PA's competition here
DGM.PA vs ALSGD.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALSGD.PA has a market cap of 7.3M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALSGD.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALSGD.PA's P/E ratio is -2.95. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALSGD.PA's ROE of -0.63%. Regarding short-term risk, DGM.PA is more volatile compared to ALSGD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check ALSGD.PA's competition here
DGM.PA vs ALCAR.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, ALCAR.PA has a market cap of 6.4M. Regarding current trading prices, DGM.PA is priced at €1.20, while ALCAR.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas ALCAR.PA's P/E ratio is -0.09. In terms of profitability, DGM.PA's ROE is -0.23%, compared to ALCAR.PA's ROE of +1.07%. Regarding short-term risk, DGM.PA is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for DGM.PA.Check ALCAR.PA's competition here
DGM.PA vs VMGBS.PA Comparison April 2026
DGM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGM.PA stands at 0. In comparison, VMGBS.PA has a market cap of 0. Regarding current trading prices, DGM.PA is priced at €1.20, while VMGBS.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGM.PA currently has a P/E ratio of -4.43, whereas VMGBS.PA's P/E ratio is N/A. In terms of profitability, DGM.PA's ROE is -0.23%, compared to VMGBS.PA's ROE of N/A. Regarding short-term risk, DGM.PA is more volatile compared to VMGBS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGM.PA.Check VMGBS.PA's competition here